A new clinical trial aims to explore innovative treatments for oral lichen planus, leveraging advanced technologies such as photobiomodulation and Er:YAG laser therapy in conjunction with clobetasol propionate. Conducted at the Medical University of Silesia, this study could provide novel insights into managing erosive lichen planus and mucosal lesions.
In this article:
- What changed?
- Study details and objectives
- Devices and interventions under evaluation
- FAQs
- Conclusion
- Disclaimer
- Further information
What changed?
The newly disclosed trial, which is currently recruiting, integrates cutting-edge device-based therapies with traditional pharmacological approaches. The interventions include photobiomodulation using a 635 nm diode laser, Er:YAG laser for mucosal tissue treatment, and clobetasol propionate (0.05%) topical application. These approaches target the symptoms of oral lichen planus, erosive lichen planus, and related mucosal lesions. This combination therapy aims to improve patient outcomes through synergistic treatment.
Study details and objectives
This clinical investigation by the Medical University of Silesia focuses on enhancing therapeutic outcomes for patients diagnosed with oral lichen planus and its erosive variant. By comparing the efficacy and safety of device-based treatments alongside a topical corticosteroid, the trial seeks to validate innovative approaches.
The trial follows a regulated methodology to comply with internationally recognized medical device regulations and good clinical practices. Researchers will assess whether the interventions can achieve symptomatic relief and encourage mucosal healing beyond the standard care regimen.
Devices and interventions under evaluation
What is photobiomodulation?
Photobiomodulation involves the application of low-level light therapy using a 635 nm diode laser. This technique stimulates cellular repair at the molecular level, making it a promising intervention in oral mucosal disorders.
How does the Er:YAG laser work?
The Er:YAG laser delivers precise energy to mucosal tissue, potentially aiding in the removal or improvement of erosive lesions. The localized application minimizes tissue damage while promoting therapeutic effects.
Role of clobetasol propionate
In this trial, clobetasol propionate (0.05%) serves as a topical corticosteroid to manage inflammation and pain. It has established efficacy in treating oral lichen planus. The trial evaluates whether its combination with modern interventions enhances clinical outcomes.
FAQ
- Who is eligible to participate? The trial is recruiting patients diagnosed with oral lichen planus or related mucosal lesions. Further details can be obtained through the trial’s official page.
- What are the expected benefits? The combination therapy intends to offer greater symptomatic relief and faster healing than standalone treatments.
- What safety measures are in place? The trial follows strict safety protocols to ensure compliance with medical device and pharmacological regulation standards.
Conclusion
This study represents a significant step forward in oral lichen planus management. By integrating photobiomodulation, Er:YAG laser, and corticosteroid therapy, researchers hope to establish a more effective standard of care. Ongoing data collection and analysis will determine the potential for widespread clinical application.
Disclaimer
This article is for informational purposes only and does not constitute legal or medical advice. Healthcare professionals should rely on regulatory standards and clinical expertise for decision-making.
Further information
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07278999?term=medical+device